Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non Operating Income: 2010-2025

Historic Non Operating Income for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to -$8.0 million.

  • Arrowhead Pharmaceuticals' Non Operating Income rose 37.37% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year decrease of 245.87%. This contributed to the annual value of -$46.8 million for FY2025, which is 311.36% down from last year.
  • Arrowhead Pharmaceuticals' Non Operating Income amounted to -$8.0 million in Q3 2025, which was up 41.02% from -$13.5 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Non Operating Income ranged from a high of $2.8 million in Q1 2022 and a low of -$13.7 million during Q4 2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Non Operating Income value was -$2.1 million (recorded in 2023), while the average stood at -$5.4 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Non Operating Income spiked by 418.24% in 2024 and then slumped by 1,339.25% in 2025.
  • Arrowhead Pharmaceuticals' Non Operating Income (Quarterly) stood at -$707,000 in 2021, then skyrocketed by 171.71% to $507,000 in 2022, then slumped by 522.88% to -$2.1 million in 2023, then tumbled by 539.13% to -$13.7 million in 2024, then skyrocketed by 37.37% to -$8.0 million in 2025.
  • Its last three reported values are -$8.0 million in Q3 2025, -$13.5 million for Q2 2025, and -$11.6 million during Q1 2025.